Published in Blood Weekly, September 11th, 2008
The one-year CUSTOM II trial, a single-arm, 100-patient prospective study designed to evaluate the safety and efficacy of XTENT's Custom NX(R) drug-eluting stent (DES) system in patients with coronary artery disease, showed no new major adverse cardiac events (MACE) since the first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.